<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>INTRODUCTION: Primary culture of <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> cells is expected to be useful for investigating the biology of <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> and predicting chemosensitivity for individual patients, yet has been hampered by technical difficulties </plain></SENT>
<SENT sid="1" pm="."><plain>We recently developed the <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> tissue-originated spheroid (CTOS) method for the primary culture of <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> cells </plain></SENT>
<SENT sid="2" pm="."><plain>In the present study, we applied this system to the primary culture of <z:e sem="disease" ids="C0007131" disease_type="Neoplastic Process" abbrv="NSCLC">non-small-cell lung cancer</z:e> </plain></SENT>
<SENT sid="3" pm="."><plain>METHODS: We used 125 surgical specimens and 18 <z:hpo ids='HP_0002202'>pleural effusions</z:hpo> for CTOS preparation </plain></SENT>
<SENT sid="4" pm="."><plain>Partially digested <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> fragments were cultured in a medium for embryonic stem cells </plain></SENT>
<SENT sid="5" pm="."><plain>CTOSs were subjected to sensitivity assay and signal transduction assay for the epidermal growth factor receptor (EGFR) <z:chebi fb="0" ids="38637">tyrosine kinase inhibitor</z:chebi> (TKI) <z:chebi fb="0" ids="114785">erlotinib</z:chebi> </plain></SENT>
<SENT sid="6" pm="."><plain>We also investigated the effects of growth factors in culturing <z:e sem="disease" ids="C0242379" disease_type="Neoplastic Process" abbrv="">lung cancer</z:e> CTOS </plain></SENT>
<SENT sid="7" pm="."><plain>RESULTS: The success rate of CTOS preparation from surgical specimens was 80.0% </plain></SENT>
<SENT sid="8" pm="."><plain>The CTOS method was also suitable for culturing <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> spheroids from <z:hpo ids='HP_0002202'>pleural effusions</z:hpo> </plain></SENT>
<SENT sid="9" pm="."><plain>CTOSs from <z:e sem="disease" ids="C0242379" disease_type="Neoplastic Process" abbrv="">lung cancer</z:e> consisted mostly of pure <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> cells </plain></SENT>
<SENT sid="10" pm="."><plain>CTOSs and CTOS-derived xenografts retained the characteristics of the original <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumors</z:e> </plain></SENT>
<SENT sid="11" pm="."><plain>In vitro assay results showed that EGFR mutation status and expression levels corresponded with <z:chebi fb="0" ids="114785">erlotinib</z:chebi> sensitivity, confirming previous clinical findings </plain></SENT>
<SENT sid="12" pm="."><plain>Furthermore, we found that neuregulin 1, a ligand of HER3, potently induced CTOS growth </plain></SENT>
<SENT sid="13" pm="."><plain>CONCLUSIONS: The CTOS method enables us to obtain primary <z:hpo ids='HP_0100526'>lung tumor</z:hpo> cells of high viability and purity </plain></SENT>
<SENT sid="14" pm="."><plain>CTOS could be a new platform for studying <z:e sem="disease" ids="C0242379" disease_type="Neoplastic Process" abbrv="">lung cancer</z:e> biology </plain></SENT>
</text></document>